GlaxoSmithKline : T2 au-dessus des attentes, guidance relevée
>Xevudy et Shingrix tirent la croissance - GSK publie un T2 au-dessus des attentes au niveau des ventes (+10% vs Cs) et de son core EPS (+18% vs Cs), grâce à une forte contribution de Xevudy (466 M£ vs Cs 97 M£) et d’un rebond significatif de Shingrix (+148%) dans la lignée du T1 (+114%). Les ventes globales ressortent en hausse de 13% CER. Après une année délicate pour Shingrix, nous observons un très fort rebond des ventes du médicament bien supérieur au consensus (...GlaxoSmithKline is a global healthcare company. Co.'s segments include: Pharmaceuticals; Vaccines; and Consumer Healthcare. The Pharmaceuticals segment is focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. The Vaccines segment has a portfolio and pipeline of vaccines to help protect people throughout life. Co. delivers vaccines to people living in over 160 countries. The Consumer Healthcare segment develops and markets consumer-preferred brands in oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.